EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

NCT01008475 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: EMD 525797 250 mg
DRUG: EMD 525797 500 mg
DRUG: EMD 525797 750 mg
DRUG: EMD 525797 1000 mg
DRUG: Cetuximab
DRUG: Irinotecan

Sponsor

Merck KGaA, Darmstadt, Germany